Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3580964 | 0.86 | CTSK (0.54) | CTSKCTSLCTSS | |
| SCHEMBL27261213 | 0.76 | CASP3 (0.43) | KMT2A | |
| SCHEMBL6036683 | 0.74 | KMT2A (0.48) | KMT2A | |
| N- (9-Fluorenylmethoxycarbonyl)-L-Leucine SCHEMBL7152831 | 0.73 | MDM4 (0.57) | KMT2APTPN1 | |
| SCHEMBL9449368 | 0.72 | PTPN1 (0.51) | CTSKKMT2APTPN1EPHX2 | |
| SCHEMBL14264912 | 0.72 | MDM4 (0.45) | CTSKCTSLCTSSKMT2APTPN1 | |
| SCHEMBL12687225 | 0.72 | PTPN1 (0.52) | KMT2APTPN1EPHX2 | |
| N- (9-Fluorenylmethoxycarbonyl)-L-Leucine SCHEMBL1002861 | 0.72 | MDM4 (0.58) | KMT2APTPN1 | |
| N- (9-Fluorenylmethoxycarbonyl)-L-Leucine SCHEMBL120560 | 0.72 | MDM4 (0.58) | KMT2APTPN1 | |
| N- (9-Fluorenylmethoxycarbonyl)-L-Leucine SCHEMBL29376158 | 0.72 | MDM4 (0.58) | KMT2APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659266-B2 | Amidine derivatives and their applications as a medicament | S.C.R.A.S. (FR) | 2010-02-09 | — | — | US | disclosed |
| US-20090018120-A1 | AMIDINE DERIVATIVES AND THEIR APPLICATIONS AS A MEDICAMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018120-A1 | AMIDINE DERIVATIVES AND THEIR APPLICATIONS AS A MEDICAMENT | CAPN2, CAPN9, CAPN1 | CTSK 148/4885CTSL 154/4885CTSS 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.